CAMP4 to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
CAMP4 (Nasdaq: CAMP) announced that Josh Mandel-Brehm, President & CEO, will present a corporate update at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2026 at 3:45 p.m. PST.
The presentation will be webcast and accessible via CAMP4's investor relations website at www.investors.camp4tx.com. A replay will be archived on the CAMP4 website for 30 days following the conference.
Positive
- None.
Negative
- None.
News Market Reaction – CAMP
On the day this news was published, CAMP declined NaN%, reflecting a moderate negative market reaction. Argus tracked a peak move of +13.0% during that session.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Sector peers show mixed moves, with examples like CUE up 6.84% and DTIL down 1.21%, while only GANX appeared in the momentum scanner, suggesting today’s setup around CAMP is stock-specific rather than a broad biotech rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 18 | Equity offering | Negative | -12.9% | Underwritten common stock offering for <b>$30.0M</b> gross proceeds at <b>$6.00</b>. |
| Dec 18 | Strategic partnership | Positive | -12.9% | GSK collaboration with <b>$17.5M</b> upfront and milestones for ASO discovery. |
| Dec 12 | Inducement grants | Neutral | +4.0% | Inducement options for <b>92,000</b> shares at <b>$6.01</b> to new employees. |
| Nov 14 | Inducement grant | Neutral | -2.7% | Single inducement option for <b>80,000</b> shares at <b>$4.39</b> to a new hire. |
| Nov 06 | Earnings & update | Positive | +7.0% | Q3 2025 results, private placement up to <b>$100M</b>, cash of <b>$75.3M</b>, and pipeline progress. |
Recent news has often led to aligned reactions, with financings drawing negative moves and positive corporate/clinical updates generally seeing supportive price action, except for the GSK collaboration selloff.
Over the last few months, CAMP has balanced financing, partnerships, and pipeline progress. A Q3 2025 update on Nov 6 highlighted a private placement of up to $100M, cash of $75.3M, and clinical advances, with shares rising 6.97%. Subsequent inducement option grants in November and December 2025 had modest, mixed reactions. On Dec 18, a $30.0M underwritten offering and a sizable GSK collaboration with $17.5M upfront saw the stock fall 12.9%, showing sensitivity to dilution despite strategic progress. Today’s conference appearance fits into this ongoing communication cadence.
Regulatory & Risk Context
An effective Form S-3 on Nov 10, 2025 registered up to $300,000,000 of securities and includes an at-the-market program of up to $100,000,000, which has already been tapped via multiple prospectus supplements, providing substantial capital-raising flexibility.
Market Pulse Summary
This announcement details a corporate update at the 44th J.P. Morgan Healthcare Conference on January 14, 2026, continuing CAMP’s recent cadence of financings, partnerships, and pipeline disclosures. Investors may contextualize this visibility alongside the November S-3 shelf for up to $300,000,000, recent equity offerings, and the GSK collaboration with $17.5M upfront and up to $440M in milestones. Future attention will likely focus on clinical progress timelines and additional capital-raising actions.
Key Terms
regulatory rna-targeting therapeutics medical
gene expression medical
webcast technical
AI-generated analysis. Not financial advice.
CAMBRIDGE, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that Josh Mandel-Brehm, President & CEO, will present a corporate update at the 44th Annual J.P. Morgan Healthcare Conference taking place in San Francisco, California, on Wednesday, January 14, 2026, at 3:45 p.m. PST.
The event will be webcast and can be accessed on the investor relations page of CAMP4’s website at www.investors.camp4tx.com. A replay of the webcast will be archived on the CAMP4 website for 30 days following the conference.
About CAMP4 Therapeutics
CAMP4 is developing disease-modifying treatments for a broad range of genetic diseases where amplifying healthy protein may offer therapeutic benefits. Our approach amplifies mRNA by harnessing a fundamental mechanism of how genes are controlled. To amplify mRNA, our therapeutic ASO drug candidates target regulatory RNAs (regRNAs), which act locally on transcription factors and are the master regulators of gene expression. CAMP4’s proprietary RAP Platform® enables the mapping of regRNAs and generation of therapeutic candidates designed to target the regRNAs associated with genes underlying haploinsufficient and recessive partial loss-of-function disorders, of which there are more than 1,200, in which a modest increase in protein expression may have the potential to be clinically meaningful. For more information, visit camp4tx.com.
Contacts
Investor Relations:
Sara Michelmore
Milestone Advisors
sara@milestone-advisorsllc.com
Media:
Jason Braco, Ph.D.
LifeSci Communications
jbraco@lifescicomms.com
FAQ
When will CAMP4 (CAMP) present at the J.P. Morgan Healthcare Conference?
Who will deliver CAMP4's corporate update at the J.P. Morgan Healthcare Conference?
How can investors watch CAMP4's webcast for the January 14, 2026 presentation?
Will CAMP4's J.P. Morgan presentation be available after the live event?
What topics will CAMP4 (CAMP) cover in the January 14, 2026 corporate update?
